SE460947B - En multiple-unit-dos komposition av l-dopa - Google Patents

En multiple-unit-dos komposition av l-dopa

Info

Publication number
SE460947B
SE460947B SE8603582A SE8603582A SE460947B SE 460947 B SE460947 B SE 460947B SE 8603582 A SE8603582 A SE 8603582A SE 8603582 A SE8603582 A SE 8603582A SE 460947 B SE460947 B SE 460947B
Authority
SE
Sweden
Prior art keywords
dopa
release
composition
hrs
granulate
Prior art date
Application number
SE8603582A
Other languages
English (en)
Swedish (sv)
Other versions
SE8603582D0 (sv
SE8603582L (sv
Inventor
C H Appelgren
E C Eskilsson
Original Assignee
Lejus Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lejus Medical Ab filed Critical Lejus Medical Ab
Priority to SE8603582A priority Critical patent/SE460947B/sv
Publication of SE8603582D0 publication Critical patent/SE8603582D0/xx
Priority to EP87850251A priority patent/EP0260236B1/en
Priority to DE8787850251T priority patent/DE3766200D1/de
Priority to ES198787850251T priority patent/ES2036221T3/es
Priority to AT87850251T priority patent/ATE58292T1/de
Priority to FI873672A priority patent/FI86689C/fi
Priority to MX007910A priority patent/MX172918B/es
Priority to DK442287A priority patent/DK442287A/da
Priority to CA000545254A priority patent/CA1298198C/en
Priority to DD87306327A priority patent/DD286107A5/de
Priority to HU873749A priority patent/HU197211B/hu
Priority to NO873589A priority patent/NO176549C/no
Priority to PT85591A priority patent/PT85591B/pt
Priority to JP62210363A priority patent/JPH0662405B2/ja
Publication of SE8603582L publication Critical patent/SE8603582L/xx
Priority to US07/378,423 priority patent/US4981695A/en
Publication of SE460947B publication Critical patent/SE460947B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
SE8603582A 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa SE460947B (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa
EP87850251A EP0260236B1 (en) 1986-08-26 1987-08-21 Composition comprising l-dopa
DE8787850251T DE3766200D1 (de) 1986-08-26 1987-08-21 L-dopa enthaltendes arzneimittel.
ES198787850251T ES2036221T3 (es) 1986-08-26 1987-08-21 Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.
AT87850251T ATE58292T1 (de) 1986-08-26 1987-08-21 L-dopa enthaltendes arzneimittel.
NO873589A NO176549C (no) 1986-08-26 1987-08-25 Fremgangsmåte for fremstilling av L-dopa-kjerner med 2 overtrekk
MX007910A MX172918B (es) 1986-08-26 1987-08-25 Composicion a base de l-3,4-dihidroxifenilalanina
FI873672A FI86689C (fi) 1986-08-26 1987-08-25 Foerfarande foer framstaellning av en multipel-unit-doskomposition, som innehaoller l-dopa som farmaceutiskt aktiv substans
DK442287A DK442287A (da) 1986-08-26 1987-08-25 Farmaceutisk praeparat indeholdende l-3,4-dihydroxyphenylalanin (l-dopa) som aktiv bestanddel og fremgangsmaade til fremstilling af et saadant praeparat
CA000545254A CA1298198C (en) 1986-08-26 1987-08-25 Composition comprising l-dopa
DD87306327A DD286107A5 (de) 1986-08-26 1987-08-25 Zusammensetzung mit mehrfachdosierung, die als pharmazeutisch wirksame verbindung entfaellt
HU873749A HU197211B (en) 1986-08-26 1987-08-25 Process for producing pharmaceutical composition containing l-dopa as active component coated with coating for regulating release of the active components
PT85591A PT85591B (pt) 1986-08-26 1987-08-26 Processo para a preparacao de composicoes farmaceuticas sob a forma de dose unitaria-multipla contendo l-dopa
JP62210363A JPH0662405B2 (ja) 1986-08-26 1987-08-26 Ｌ―ドーパ含有組成物
US07/378,423 US4981695A (en) 1986-08-26 1989-07-12 Composition comprising L-dopa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (3)

Publication Number Publication Date
SE8603582D0 SE8603582D0 (sv) 1986-08-26
SE8603582L SE8603582L (sv) 1988-02-27
SE460947B true SE460947B (sv) 1989-12-11

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Country Status (15)

Country Link
US (1) US4981695A (fi)
EP (1) EP0260236B1 (fi)
JP (1) JPH0662405B2 (fi)
AT (1) ATE58292T1 (fi)
CA (1) CA1298198C (fi)
DD (1) DD286107A5 (fi)
DE (1) DE3766200D1 (fi)
DK (1) DK442287A (fi)
ES (1) ES2036221T3 (fi)
FI (1) FI86689C (fi)
HU (1) HU197211B (fi)
MX (1) MX172918B (fi)
NO (1) NO176549C (fi)
PT (1) PT85591B (fi)
SE (1) SE460947B (fi)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
DK1408964T3 (da) * 2001-07-26 2007-05-21 Merck Patent Gmbh Hidtil ukendt anvendelse af 2-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman og fysiologisk acceptable salte deraf
AU2003222045A1 (en) * 2002-03-21 2003-10-08 Martin C. Hinz Serotonin and catecholamine system segment optimization techonology
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
KR20060109922A (ko) * 2003-10-31 2006-10-23 알자 코포레이션 가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형
JP2007517776A (ja) * 2003-12-09 2007-07-05 スフェリックス， インコーポレイテッド カテコール官能基を有する生体接着性ポリマー
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20090227673A1 (en) * 2006-01-13 2009-09-10 Bao Ting Zhu Method and Composition for the Treatment of Parkinson's Disease
US20100226855A1 (en) * 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (fi) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
EP0260236B1 (en) 1990-11-14
FI86689B (fi) 1992-06-30
JPS63139128A (ja) 1988-06-10
US4981695A (en) 1991-01-01
HUT44438A (en) 1988-03-28
SE8603582D0 (sv) 1986-08-26
PT85591B (pt) 1990-05-31
FI873672A (fi) 1988-02-27
EP0260236A1 (en) 1988-03-16
DK442287D0 (da) 1987-08-25
ES2036221T3 (es) 1993-05-16
MX172918B (es) 1994-01-21
ATE58292T1 (de) 1990-11-15
HU197211B (en) 1989-03-28
DD286107A5 (de) 1991-01-17
FI86689C (fi) 1992-10-12
DE3766200D1 (de) 1990-12-20
NO873589D0 (no) 1987-08-25
JPH0662405B2 (ja) 1994-08-17
NO176549B (no) 1995-01-16
NO176549C (no) 1995-04-26
SE8603582L (sv) 1988-02-27
PT85591A (en) 1987-09-01
CA1298198C (en) 1992-03-31
DK442287A (da) 1988-02-27
NO873589L (no) 1988-02-29
FI873672A0 (fi) 1987-08-25

Similar Documents

Publication Publication Date Title
SE460947B (sv) En multiple-unit-dos komposition av l-dopa
US8101209B2 (en) Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2518882B2 (ja) 被覆膜及びそれから調製された組成物
ES2226886T3 (es) Forma de administracion de accion retardada que contiene sacarinato de tramadol.
US4728512A (en) Formulations providing three distinct releases
US4309404A (en) Sustained release pharmaceutical compositions
US6214385B1 (en) Controlled absorption diltiazem pharmaceutical formulation
EP0711152B1 (en) Powder-layered oral dosage forms
US4462991A (en) Method of increasing oral absorption of polar bioactive agents
US5122384A (en) Oral once-per-day organic nitrate formulation which does not induce tolerance
CA1323576C (en) Long acting diclofenac sodium preparation
AU2007267159B2 (en) Lipoic acid pellets
US7611730B2 (en) Tramadol-based medicament
US20110189269A1 (en) Extended release composition containing tramadol
US20070098786A1 (en) Enteric valproic acid
IE58278B1 (en) Long-acting formulation of cefaclor
EP0418597A2 (en) Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
US20030215506A1 (en) Methods and compositions for enhancement of creatine transport
KR20190080875A (ko) 모발 성장 자극을 위한 알파-케토부티레이트, 알파-케토글루타레이트, 및 2-하이드록시부티레이트
US6994873B2 (en) Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration
JP2009514784A (ja) 経口リバビリン医薬組成物
SE460946B (sv) En multipel-unit-dos komposition av kinidinglukonat
US20040170688A1 (en) Enteric formulation of fluoxetin
IE62643B1 (en) Synergistic combination of decarboxylase inhibitors and L-dopa pellets
WO2023278300A1 (en) Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8603582-1

Effective date: 19920306

Format of ref document f/p: F